Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

1.12AUD
27 Jul 2016
Change (% chg)

$-0.03 (-2.17%)
Prev Close
$1.15
Open
$1.16
Day's High
$1.16
Day's Low
$1.12
Volume
704,329
Avg. Vol
1,126,949
52-wk High
$4.05
52-wk Low
$1.01

Select another date:

Fri, Jul 1 2016

BRIEF-Mesoblast provides update on heart failure trial and funding of clinical operations

* Mesoblast provides update on heart failure trial and funding of clinical operations Source text for Eikon: Further company coverage: )

UPDATE 1-Mesoblast shares slump to 2009 low as Teva ends partnership

* Mesoblast shares plummet 42 pct to lows not seen since 2009

Mesoblast regains full rights to stem cell heart failure treatment

Mesoblast Ltd on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure, which is currently in late stage testing, from Teva Pharmaceutical Industries.

Mesoblast regains full rights to stem cell heart failure treatment

Mesoblast Ltd on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure, which is currently in late stage testing, from Teva Pharmaceutical Industries.

Mesoblast regains full rights to stem cell heart failure treatment

June 13 Mesoblast Ltd on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure, which is currently in late stage testing, from Teva Pharmaceutical Industries.

Select another date: